5,295 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by MGO One Seven LLC

MGO One Seven LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,295 shares of the medical device company’s stock, valued at approximately $412,000.

A number of other large investors have also bought and sold shares of the business. Geode Capital Management LLC increased its stake in DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock worth $775,256,000 after purchasing an additional 56,094 shares in the last quarter. Jennison Associates LLC grew its stake in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares in the last quarter. Norges Bank bought a new position in shares of DexCom during the 4th quarter worth approximately $385,367,000. Charles Schwab Investment Management Inc. grew its stake in shares of DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after acquiring an additional 91,051 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in shares of DexCom by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company’s stock worth $144,152,000 after acquiring an additional 201,181 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $99.00.

DexCom Stock Down 0.7 %

DXCM opened at $71.18 on Tuesday. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $27.91 billion, a P/E ratio of 49.78, a P/E/G ratio of 2.30 and a beta of 1.50. The stock has a fifty day moving average of $72.72 and a 200-day moving average of $76.74.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.